CommercialCoverageLow impact
08.02.46, Zevaskyn™ (prademagene zamikeracel)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Nov 3, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy for Zevaskyn™ (prademagene zamikeracel) has been established, effective November 3, 2025. This is a brand new pharmacy policy that will likely establish coverage criteria and billing requirements for this medication.
Action Required
By November 3, 2025: Billing team should review the complete policy document at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Zevaskyn™. Monitor for additional guidance as this is a new medication policy.